The current financial score of Integra Lifesciences Holdings Corp is 7.35. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 411.18M, representing a year-over-year increase of 2.27%, while its net profit experienced a year-over-year increase of 374.83%.
The current valuation score of Integra Lifesciences Holdings Corp is 8.11. Its current P/E ratio is -2.29, which is -4798.50% below the recent high of 107.70 and -13063.29% above the recent low of -301.73.
The current earnings forecast score of Integra Lifesciences Holdings Corp is 6.50. The average price target is 15.43, with a high of 23.00 and a low of 13.00.
The current price momentum score of Integra Lifesciences Holdings Corp is 6.28. Currently, the stock price is trading between the resistance level at 16.05 and the support level at 12.58, making it suitable for range-bound swing trading.
The current institutional shareholding score of Integra Lifesciences Holdings Corp is 10.00. The latest institutional shareholding proportion is 106.43%, representing a quarter-over-quarter increase of 10.94%.
The current risk assessment score of Integra Lifesciences Holdings Corp is 5.01. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.